Antidotes & Anecdotes

This CME-accredited satellite symposium, chaired by Professor Dr Harald Darius, took place at Acute Cardiovascular Care 2016 in Lisbon, Portugal.

“Antidotes & Anecdotes: Real-world control in NOAC therapy” was a 60-minute, interactive session that aimed to discuss the emergency management of patients receiving oral anticoagulants, dispel fear of anticoagulation side effects and inspire clinicians to optimise their management strategies for patients with atrial fibrillation. The symposium has been transcribed into an enduring eLearning module, which is available on our dedicated eLearning platform.

Access eLearning

  • Purpose of the meeting

    The programme’s key aim was to provide the audience with expert insight into the emergency management of patients receiving NOACs and, in doing so, inspire clinicians to optimise anticoagulation care in at-risk patients.

    The intended audience included cardiologists, GPs, nurses and any other healthcare professional with an interest or role in the management of atrial fibrillation.

  • Learning objectives

    The satellite symposium aimed to ensure that participants will:

    • Implement an optimised course of oral anticoagulants in all eligible patients
    • Be able to describe management options for patients experiencing internal bleeding while receiving NOACs
    • Be able to recite the fundamental pharmacodynamics of NOAC reversal agents
    • Be able to recognise the factors that affect the choice and dose of oral anticoagulants
  • Programme
    Time Title Speaker

    Chair's welcome

    • Harald Darius

    Management of patients on NOACs: tales from the ER

    The lack of a specific and evidence-based reversal strategy has limited the uptake of NOAC therapy over conventional VKA anticoagulation. In fact, major bleeding complications are unusual, and most can be managed with general measures only. For the rare life-threatening bleed, a specific reversal agent – an antidote – would streamline care and assure clinicians. In this presentation, we explore the use of this antidote and how it has influenced emergency patient management in these rare, life-threatening bleeds.

    • Charles Pollack

    A closer look at NOAC reversal agents

    While NOACs cannot be reversed through ordinary means, a number of reversal agents have been developed in order to allow rapid inhibition of the anticoagulant and return to natural haemostatic potential. This talk will explore the pharmacology of these reversal agents, including their mechanisms of action, posology and side effects noted in their latest clinical trials.

    • Peter Verhamme

    The upstream impact: how new developments affect your patients

    We are entering an age in which NOACs can be rapidly reversed in cases of emergency. But what does this mean for your patients? How should this increased control impact prescribing practices where they are available?

    • Harald Darius

    Chair's Summary

    • Harald Darius
  • Speakers

    Professor Dr Charles Pollack

    Thomas Jefferson University Hospital

    Philadelphia, USA

    Professor Dr Harald Darius

    Vivantes Klinikum Neukölln

    Berlin, Germany

    Professor Dr Peter Verhamme

    University Hospitals Leuven

    Leuven, Belgium

  • Funding

    This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and satellite symposium organiser for this programme.